• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2020 Fiscal Year Annual Research Report

Calreticulin変異での骨髄増殖性疾患に伴う肺高血圧症のメカニズム解明

Research Project

Project/Area Number 19K17532
Research InstitutionFukushima Medical University

Principal Investigator

横川 哲朗  福島県立医科大学, 医学部, 助教 (80748773)

Project Period (FY) 2019-04-01 – 2021-03-31
KeywordsCALR変異 / 肺高血圧症 / 骨髄増殖性疾患
Outline of Annual Research Achievements

Calreticulin(CALR)変異は2013年に報告された、骨髄増殖性疾患(真性赤血球増多症、本態性血小板血症、骨髄線維症)の2番目に多い遺伝子変異の一つである。骨髄増殖性疾患は肺高血圧症をしばしば合併する。肺高血圧症は骨髄増殖性疾患における予後不良因子の一つであるが、その発症メカニズムについては不明である。今回、CALR変異ノックインマウスを用いて、骨髄由来CALR変異陽性細胞の肺高血圧症における意義を検討した。当施設で有するCRISPR-Cas9法によって作成した2種類のCALR変異ノックインマウスの内、本態性血小板血症と似た病態を呈する10-deletionのCALR変異ノックインマウスを用いた。結果、骨髄由来CALR変異が、肺動脈中膜肥厚を伴って、低酸素誘導性肺高血圧症モデルを悪化させ、エンドセリン1の肺における発現を上昇させた。さらに、低酸素誘導性モデルマウスの肺動脈周囲にはマクロファージが浸潤していたため、マクロファージを用いたin vitroの実験を行った。CALR変異ノックインマウスの骨髄細胞を培養し、CALR変異陽性-骨髄由来マクロファージを作成。そのマクロファージでエンドセリン1の発現やSTAT3のリン酸化が増加していた。以上の結果より、CALR変異陽性骨髄細胞が、マクロファージやエンドセリン1を介したメカニズムによって、肺高血圧症を増悪させることを明らかとした。本研究成果は論文にて報告した。
また、循環器疾患患者におけるCALR変異の頻度をリアルタイムPCR法にて調べたが、循環器内科へ通院中の肺高血圧症患者において、CALR変異のアレルバーデンが高値となる患者を認めなかった。

  • Research Products

    (13 results)

All 2021 2020

All Journal Article (5 results) (of which Peer Reviewed: 5 results,  Open Access: 5 results) Presentation (8 results) (of which Int'l Joint Research: 4 results)

  • [Journal Article] Clonal hematopoiesis and JAK2V617F mutations in patients with cardiovascular disease.2021

    • Author(s)
      Yokokawa T, Misaka T, Kimishima Y, Wada K, Minakawa K, Kaneshiro T, Yoshihisa A, Ikeda K, Takeishi Y.
    • Journal Title

      JACC: CardioOncology

      Volume: 3 Pages: 134-136

    • Peer Reviewed / Open Access
  • [Journal Article] Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice.2021

    • Author(s)
      Minakawa K, Yokokawa T, Ueda K, Nakajima O, Misaka T, Kimishima Y, Wada K, Tomita Y, Miura S, Sato Y, Miura K, Sugimoto K, Nakazato K, Nollet KE, Ogawa K, Ikezoe T, Hashimoto Y, Takeishi Y, Ikeda K.
    • Journal Title

      J Hematol Oncol

      Volume: 14 Pages: 52

    • DOI

      10.1186/s13045-021-01064-8.

    • Peer Reviewed / Open Access
  • [Journal Article] Crucial role of hematopoietic JAK2V617F in the development of aortic aneurysms.2021

    • Author(s)
      Yokokawa T, Misaka T, Kimishima Y, Wada K, Minakawa K, Sugimito K, Ishida T, Morishita S, Komatsu N, Ikeda K, Takeishi Y.
    • Journal Title

      Haematologica

      Volume: - Pages: -

    • DOI

      10.3324/haematol.2020.264085.

    • Peer Reviewed / Open Access
  • [Journal Article] Anti-mitochondrial antibodies in patients with dilated cardiomyopathy.2021

    • Author(s)
      Yokokawa T, Yoshihisa A, Misaka T, Sato T, Kaneshiro T, Oikawa M, Kobayashi A, Yamaki T, Kunii H, Takeishi Y.
    • Journal Title

      Intern Med

      Volume: 60 Pages: 201-208

    • DOI

      10.2169/internalmedicine.5422-20.

    • Peer Reviewed / Open Access
  • [Journal Article] Endothelin-1 upregulates activin receptor-like kinase-1 expression via G i/RhoA/Sp-1/Rho kinase pathways in human pulmonary arterial endothelial cells.2021

    • Author(s)
      Sugimoto K, Yokokawa T, Misaka T, Kaneshiro T, Yamada S, Yoshihisa A, Nakazato K, Takeishi Y.
    • Journal Title

      Front Cardiovasc Med

      Volume: 8 Pages: 648981

    • DOI

      10.3389/fcvm.2021.648981.

    • Peer Reviewed / Open Access
  • [Presentation] JAK2V617F-positive myeloproliferative neoplasm is associated with aortic aneurysm2021

    • Author(s)
      Yokokawa T, Misaka T, Kimishima Y, Wada K, Sugimoto K, Ishida T, Takeishi Y.
    • Organizer
      第85回 日本循環器学会学術集会
  • [Presentation] Clinical significance of myeloproliferative neoplasm driver mutation-mediated clonal hematopoiesis in patients with cardiovascular diseases2021

    • Author(s)
      和田健斗, 三阪智史, 横川哲朗, 君島勇輔, 皆川敬冶, 義久精臣, 池田和彦, 竹石恭知
    • Organizer
      第85回 日本循環器学会学術集会
  • [Presentation] Crucial role of Jak2V617f-positive myeloproliferative neoplasm in the development of aortic aneurysm.2020

    • Author(s)
      Yokokawa T, Misaka T, Kimishima Y, Wada K, Minakawa K, Sugimoto K, Ishida T, Ikeda K, Takeishi Y.
    • Organizer
      American Heart Association Scientific Session 2020
    • Int'l Joint Research
  • [Presentation] Clinical significance of clonal hematopoiesis with JAK2V617F in patients with cardiovascular diseases2020

    • Author(s)
      Wada K, Misaka T, Yokokawa T, Kimishima Y, Minakawa K, Kaneshiro T, Yoshihisa A, Ikeda K, Takeishi Y
    • Organizer
      American Heart Association Scientific Session 2020
    • Int'l Joint Research
  • [Presentation] Endothelin-1 increases ACVRL-1 expression at the transcriptional and post-transcriptional levels in human pulmonary arterial endothelial cells via Gi, RhoA and Rho kinase pathway with involvement of Sp-12020

    • Author(s)
      Sugimoto K, Yokokawa T, Misaka T, Yokokawa S, Nakazato K, Ishida T, Takeishi Y
    • Organizer
      American Heart Association Scientific Session 2020
    • Int'l Joint Research
  • [Presentation] Hematopoietic JAK2V617F mutation exacerbates aortic aneurysm development.2020

    • Author(s)
      Yokokawa T, Misaka T, Kimishima Y, Wada K, Minakawa K, Sugimoto K, Ishida T, Ikeda K, Takeishi Y.
    • Organizer
      The 64th Annual Scientific Meeting of The Korean Society of Cardiology
    • Int'l Joint Research
  • [Presentation] Clinical significance of clonal hematopoiesis with JAK2V617F in patients with cardiovascular disease2020

    • Author(s)
      Wada K, Misaka T, Yokokawa T, Kimishima Y, Minakawa K, Kaneshiro T, Yoshihisa A, Ikeda K, Takeishi Y
    • Organizer
      The 4th JCS Council Forum on Basic CardioVascular Research
  • [Presentation] Crucial role of hematopoietic JAK2V617F mutation in the development of aortic aneurysms2020

    • Author(s)
      Yokokawa T, Misaka T, Kimishima Y, Wada K, Minakawa K, Sugimoto K, Ishida T, Ikeda K, Takeishi Y.
    • Organizer
      The 4th JCS Council Forum on Basic CardioVascular Research

URL: 

Published: 2021-12-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi